StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.70−0.06 (-2.17%)

Close on Nov 20, 2026Market cap $109.34MP/E –Yield –

OnKure Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

OnKure Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$47.86M. For fiscal 2025 it was -$51.87M. The highest annual figure on record is -$18.56M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.87M–
FY2024Dec 31, 2024-$51.17M–
FY2023Dec 31, 2023-$34.79M–
FY2022Dec 31, 2022-$47.71M–
FY2021Dec 31, 2021-$38.18M–
FY2020Dec 31, 2020-$18.56M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.36M–
Q1 FY2026Mar 31, 2026-$12.94M–
Q4 FY2025Dec 31, 2025-$11.52M–
Q3 FY2025Sep 30, 2025-$13.04M–
Q2 FY2025Jun 30, 2025-$13.29M–
Q1 FY2025Mar 31, 2025-$14.02M–
Q4 FY2024Dec 31, 2024-$23.37M-350.4%
Q3 FY2024Sep 30, 2024-$10.68M–
Q2 FY2024Jun 30, 2024-$6.48M–
Q1 FY2024Mar 31, 2024-$10.64M–
Q4 FY2023Dec 31, 2023$9.33M–
Q3 FY2023Sep 30, 2023-$18.79M–
Q2 FY2023Jun 30, 2023-$16.12M–
Q1 FY2023Mar 31, 2023-$9.22M–
Q4 FY2022Dec 31, 2022-$15.86M–
Q3 FY2022Sep 30, 2022-$10.82M–
Q2 FY2022Jun 30, 2022-$11.98M–
Q1 FY2022Mar 31, 2022-$9.04M–
Q4 FY2021Dec 31, 2021-$10.11M–
Q3 FY2021Sep 30, 2021-$9.75M–
Q2 FY2021Jun 30, 2021-$9.71M–
Q1 FY2021Mar 31, 2021-$8.61M–
Q4 FY2020Dec 31, 2020-$5.43M–
Q3 FY2020Sep 30, 2020-$5.75M–
Q2 FY2020Jun 30, 2020-$2.94M–
Q1 FY2020Mar 31, 2020-$4.45M–

More OnKure Therapeutics figures

See a number that looks wrong?